Anti-inflammatory activity of a specific turmeric extract
View Patent ↗Disclosed herein are mixtures of turmeric extract oils. One mixture of turmeric oils is the hexane soluble fraction obtained by dissolving turmeric powder in hexane to form a hexane mixture, filtering the hexane mixture and evaporating the hexane from the turmeric oil mixture. A more refined turmeric oil combination is the oil left after the turmeric oil mixture is dissolved in hexane, placed on a silica gel/hexane chromatography column, and eluted with hexane into fractions that were then evaporated, thereby leaving the refined turmeric oil combination. Also disclosed are methods for treating inflammation, arthritis and rheumatoid arthritis and a pharmaceutical dosage form of the refined turmeric oil combination.
1. A turmeric oil extract for treating inflammation comprising fractions 6–10 obtained by dichloromethane-methanol (1:1 v/v) extraction followed by a gradient elution using water (A) and acetonitrile (B), the gradient comprising 0 min 40% B, 10 min 60% B, 32 min 100% B, 38 min 100% B and 40 min 40% B and chromatographically separated using a Luna C 18 (2) column with a C 18 guard column to produce Fractions numbered 6–10, wherein Fractions 6–10 do not contain curcuminoids and comprise about 38.8% of the total mass of all extract fractions that elute off of the column.
2. A method of treating inflammation, the method comprising administering to a mammal suffering therefrom a sufficient amount of a turmeric oil extract to ameliorate the symptoms of inflammation, wherein the extract comprises Fractions 6–10 obtained by dichloromethane-methanol (1:1 v/v) extraction followed by a gradient elution using water (A) and acetonitrile (B), the gradient comprising 0 min 40% B, 10 mm 60% B, 32 min 100% B, 38 min 100% B and 40 mm 40% B and chromatographically separated using a Luna C 18 (2) column with a C 18 guard column to produce Fractions numbered 6–10, and wherein the extract does not contain curcuminoids and comprises about 38.8% of the total mass of all extract fractions that elute off of the column.
3. The method of claim 2 wherein the inflammation is arthritis.
4. The method of claim 3 wherein the arthritis is rheumatoid arthritis.
5. A method of treating inflammation without inhibiting COX-2 expression in a mammal, the method comprising administering to a mammal a sufficient amount of a turmeric oil extract to ameliorate the symptoms of inflammation, wherein the extract comprises Fractions 6–10 obtained by dichloromethane-methanol (1:1 v/v) extraction followed by a gradient elution using water (A) and acetonitrile (B), the gradient comprising 0 min 40% B, 10 min 60% B, 32 min 100% B, 38 min 100% B and 40 min 40% B and chromatographically separated using a Luna C 18 (2) column with a C 18 guard column to produce Fractions numbered 6–10, and wherein the extract does not contain curcuminoids and comprises about 38.8% of the total mass of all extract fractions that elute off of the column.
6. A pharmaceutical composition for treating inflammation comprising a turmeric oil extract and a pharmaceutically compatible excipient, wherein the extract comprises Fractions 6–10 obtained by dichloromethane-methanol (1:1 v/v) extraction followed by a gradient elution using water (A) and acetonitrile (B), the gradient comprising 0 min 40% B, 10 min 60% B, 32 min 100% B, 38 min 100% B and 40 min 40% B and chromatographically separated using a Luna C 18 (2) column with a C 18 guard column to produce Fractions numbered 6–10, and wherein the extract does not contain curcuminoids and comprises about 38.8% of the total mass of all extract fractions that elute off of the column.
7. A nutraceutical composition for treating inflammation comprising a turmeric oil extract, wherein the extract comprises Fractions 6–10 obtained by dichloromethane-methanol (1:1 v/v) extraction followed by a gradient elution using water (A) and acetonitrile (B), the gradient comprising 0 min 40% B, 10 min 60% B, 32 min 100% B, 38 min 100% B and 40 min 40% B and chromatographically separated using a Luna C 18 (2) column with a C 18 guard column to produce Fractions numbered 6–10, and wherein the extract does not contain curcuminoids and comprises about 38.8% of the total mass of all extract fractions that elute off of the column.